How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1906-1914

  Auray Blais, Christiane ^a   Ntwari, Aimé ^a   Clarke, Joe T R ^a   Warnock, David G ^b   Oliveira, João Paulo ^c   Young, Sarah P ^d   Millington, David S ^d   Bichet, Daniel G ^e   Sirrs, Sandra ^f   West, Michael L ^g   Casey, Robin ^h   Hwu, Wuh Liang ⁱ   Keutzer, Joan M ^j   Zhang, X Kate ^j   Gagnon, René ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b University of Alabama at Birmingham   (United States)

^c University of Porto   (Portugal)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h ALBERTA CHILDREN'S HOSPITAL   (Canada)

ⁱ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^j GENZYME CORPORATION   (United States)

more..

Author keywords

Fabry disease; LC MS MS; Liquid chromatography tandem mass spectrometry; Time of flight mass spectrometry

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; BIOLOGICAL MARKER; CREATININE; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; UNCLASSIFIED DRUG; CREATINE; DRUG DERIVATIVE; GLOBOTRIAOSYL LYSOSPHINGOLIPID; GLYCOLIPID; PSYCHOSINE; SPHINGOLIPID; SPHINGOSYL BETA GLUCOSIDE; SPHINGOSYL BETA-GLUCOSIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GENE MUTATION; HUMAN; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; URINARY EXCRETION; URINE LEVEL; VALIDATION PROCESS; ADOLESCENT; CASE CONTROL STUDY; CHILD; DRUG ANTAGONISM; ENZYMOLOGY; KIDNEY; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PRESCHOOL CHILD; REPRODUCIBILITY; SEX DIFFERENCE; STANDARD; URINALYSIS; URINE;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CREATINE; FABRY DISEASE; FEMALE; GLYCOLIPIDS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PSYCHOSINE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SEX FACTORS; SPHINGOLIPIDS; URINALYSIS; YOUNG ADULT;

EID: 77957756430     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.038     Document Type: Article

References (30)

1. Clarke J.T.R. Narrative review: Fabry disease. Ann Intern Med 2007, 146:425-433.
2. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
3. Spada M., Pagliardini S., Yasuda M., et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006, 79:31-40.
4. Desnick R.J., Brady R., Barranger J., et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003, 138:338-346.
5. Elleder M., Bradova V., Smid F., et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990, 417:449-455.
6. Nakao S., Kodama C., Takenaka T., et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003, 64:801-807.
7. Schiffmann R., Kopp J.B., Austin H.A., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
8. Eng C.M., Guffon N., Wilcox W.R., et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001, 345:9-16.
9. Schiffmann R., Ries M., Timmons M., Flaherty J.T., Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006, 21:345-354.
10. Auray-Blais C., Cyr D., Ntwari A., et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 2008, 93:331-340.
11. 3/creatinine biomarkers for Fabry disease: issues to consider. Mol Genet Metab 2009, 97:237.
12. Schaefer E., A-Gal M.A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl 2005, 94:87-92. discussion 79.
13. Branton M.H., Schiffmann R., Sabnis S.G., et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002, 81:122-138.
14. 3 concentrations. J Inherit Metab Dis 2007, 30:68-78.
15. Whitfield P.D., Calvin J., Hogg S., et al. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J Inherit Metab Dis 2005, 28:21-33.
16. Aerts J.M., Groener J.E., Kuiper S., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008, 105:2812-2817.
17. Farwanah H., Wirtz J., Kolter T., Raith K., Neubert R.H., Sandhoff K. Normal phase liquid chromatography coupled to quadrupole time-of-flight atmospheric pressure chemical ionization mass spectrometry for separation, detection and mass spectrometric profiling of neutral sphingolipids and cholesterol. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:2976-2982.
18. Mills K., Morris P., Lee P., et al. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 2005, 28:35-48.
19. Auray-Blais C., Millington D.S., Young S.P., Clarke J.T.R., Schiffmann R. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease. J Inherit Metab Dis 2009, 32:303-308.
20. Auray-Blais C., Cyr D., Mills K., Giguère R., Drouin R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J Inherit Metab Dis 2007, 30:106.
21. Zhang X.K., Elbin C.S., Chuang W.L., et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 2008, 54:1725-1728.
22. Chasson A.L., Grady H.J., Stanley M.A. Determination of creatinine by means of automatic chemical analysis. Tech Bull Regist Med Technol 1960, 30:207-212.
23. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
24. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
25. Tahir H., Jackson L.L., Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007, 18:2609-2617.
26. Schiffmann R., Warnock D.G., Banikazemi M., et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009, 24:2102-2111.
27. West M.L., Nicholls K., Mehta A., et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009, 20:1132-1139.
28. Schiffmann R., Waldek S., Benigni A., Auray-Blais C. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol 2010, 5:360-364.
29. Barr C., Clarke J.T.R., Ntwari A., Drouin R., Auray-Blais C. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6months. Mol Genet Metab 2009, 97:278-283.
30. Redonnet-Vernhet I., Ploos van Amstel J.K., Jansen R.P., Wevers R.A., Salvayre R., Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 1996, 33:682-688.